inflammatix.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $912.31MM
Inflammatix is a biotechnology company which offers diagnostic testing solutions to healthcare providers and laboratories. This company was founded by Timothy Sweeney MD, Ph.D, Jonathan Romanowsky, and Purvesh Khatri Ph.D in 2016 and is headquartered in Sunnyvale, CA. Inflammatix’s platform leverages host response-based diagnostics striving to detect infections and inflammatory diseases by analyzing gene expression data. The company aims to improve diagnostic accuracy and patient outcomes by delivering timely, actionable information intended for conditions such as sepsis, infections, and other immune-related disorders.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/12/2024 | Series E-1 | $6.44MM | $xx.xx | $236.23MM | D1 Capital Partners, Iberis Capital, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, RAW Ventures, Think.Health Ventures, Vesalius Biocapital | |
Price per Share
$xx.xx
Shares Outstanding
54,406,768
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
D1 Capital Partners, Iberis Capital, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, RAW Ventures, Think.Health Ventures, Vesalius Biocapital
|
||||||
09/12/2024 | Series E | $24.13MM | $xx.xx | $236.23MM | D1 Capital Partners, Iberis Capital, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, RAW Ventures, Think.Health Ventures, Vesalius Biocapital | |
Price per Share
$xx.xx
Shares Outstanding
163,139,919
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
D1 Capital Partners, Iberis Capital, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, RAW Ventures, Think.Health Ventures, Vesalius Biocapital
|
||||||
09/12/2024 | Series E-2 | $26.43MM | $xx.xx | $236.23MM | D1 Capital Partners, Iberis Capital, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, RAW Ventures, Think.Health Ventures, Vesalius Biocapital | |
Price per Share
$xx.xx
Shares Outstanding
178,714,497
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
D1 Capital Partners, Iberis Capital, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, RAW Ventures, Think.Health Ventures, Vesalius Biocapital
|
||||||
03/16/2021 | Series D-1 | $107.4MM | $xx.xx | $307.28MM | D1 Capital Partners, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, Think.Health Ventures | |
Price per Share
$xx.xx
Shares Outstanding
260,158,640
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
D1 Capital Partners, Khosla Ventures, Northpond Ventures, Osf Healthcare Ventures, Think.Health Ventures
|
||||||
01/10/2020 | Series C-1 | $34.1MM | $xx.xx | $107.77MM | Grey Sky Venture Partners, Khosla Ventures, Northpond Ventures, Think.Health Ventures | |
Price per Share
$xx.xx
Shares Outstanding
137,025,180
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Grey Sky Venture Partners, Khosla Ventures, Northpond Ventures, Think.Health Ventures
|
||||||
10/18/2018 | Series B-1 | $14.29MM | $xx.xx | $41.69MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
82,509,180
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
03/17/2017 | Series A-1 | $4.12MM | $xx.xx | $10.31MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
61,923,100
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|